Imagine. Steve Jobs comes onstage, firing up his iPad to project beautiful tables and charts of money. From the stage sofa, he announces Apple’s stock split (“Now the little investor can buy 70 shares instead of only ten”). He then tells about the big dividend money being distributed to shareholders (“We trust you to... »
According to what we read and hear, the economy, housing and the stock market are either overheated or tepid. Even the Fed vacillates between hot inflation and cold deflation worries. The reality? That glow that we see everywhere is Goldilocks’ “just right” warmth, evidence of neither a burgeoning bonfire nor a sputtering flameout. This... »
With investors typically looking six months ahead, we should be seeing a good spark of interest in homebuilders stocks. But, instead, there is a collective holding of breaths. There are three key drivers for this hesitation. More importantly, the wait-and-see attitude is setting up the possibility of a “who knew?” run-up in homebuilder stocks.... »
“They” are at it again, trying to trip up our investment plans. A deluge of articles warns that “momentum” investing (i.e., investors chasing performance) created a bubble-like environment that is now popping. The conclusion? Run from growth, and focus on dividends and safety. That great advice for April 2000 and April 2009 is terrible... »
Looking at this week’s (4/7 and 4/8) action, biotech stocks are showing signs of support. Technical patterns, investor behavior and takeover interest are indicating that current prices offer a buying opportunity. Here is what has changed. This article is published on Forbes.com »
Biotech stocks dropped again, but four reasons indicate that waiting remains the best strategy. Attitudes of investors appear not to have turned negative yet and, therefore, biotech stocks are susceptible to more selling. The biotech sell-off, while possibly presenting trading opportunities, looks problematic for long-term investors. While an imminent collapse doesn’t look likely, biotech’s... »
